TY - JOUR
T1 - Preoperative prediction of diffuse glioma type and grade in adults
T2 - a gadolinium-free MRI-based decision tree
AU - Azizova, Aynur
AU - Prysiazhniuk, Yeva
AU - Wamelink, Ivar J.H.G.
AU - Cakmak, Marcus
AU - Kaya, Elif
AU - Wesseling, Pieter
AU - de Witt Hamer, Philip C.
AU - Verburg, Niels
AU - Petr, Jan
AU - Barkhof, Frederik
AU - Keil, Vera C.
N1 - © 2024. The Author(s).
PY - 2025/3
Y1 - 2025/3
N2 - Objectives: To develop a gadolinium-free MRI-based diagnosis prediction decision tree (DPDT) for adult-type diffuse gliomas and to assess the added value of gadolinium-based contrast agent (GBCA) enhanced images. Materials and methods: This study included preoperative grade 2–4 adult-type diffuse gliomas (World Health Organization 2021) scanned between 2010 and 2021. The DPDT, incorporating eleven GBCA-free MRI features, was developed using 18% of the dataset based on consensus readings. Diagnosis predictions involved grade (grade 2 vs. grade 3/4) and molecular status (isocitrate dehydrogenase (IDH) and 1p/19q). GBCA-free diagnosis was predicted using DPDT, while GBCA-enhanced diagnosis included post-contrast images. The accuracy of these predictions was assessed by three raters with varying experience levels in neuroradiology using the test dataset. Agreement analyses were applied to evaluate the prediction performance/reproducibility. Results: The test dataset included 303 patients (age (SD): 56.7 (14.2) years, female/male: 114/189, low-grade/high-grade: 54/249, IDH-mutant/wildtype: 82/221, 1p/19q-codeleted/intact: 34/269). Per-rater GBCA-free predictions achieved ≥ 0.85 (95%-CI: 0.80–0.88) accuracy for grade and ≥ 0.75 (95%-CI: 0.70–0.80) for molecular status, while GBCA-enhanced predictions reached ≥ 0.87 (95%-CI: 0.82–0.90) and ≥ 0.77 (95%–CI: 0.71–0.81), respectively. No accuracy difference was observed between GBCA-free and GBCA-enhanced predictions. Group inter-rater agreement was moderate for GBCA-free (0.56 (95%-CI: 0.46–0.66)) and substantial for GBCA-enhanced grade prediction (0.68 (95%-CI: 0.58–0.78), p = 0.008), while substantial for both GBCA-free (0.75 (95%-CI: 0.69–0.80) and GBCA-enhanced (0.77 (95%-CI: 0.71–0.82), p = 0.51) molecular status predictions. Conclusion: The proposed GBCA-free diagnosis prediction decision tree performed well, with GBCA-enhanced images adding little to the preoperative diagnostic accuracy of adult-type diffuse gliomas. Key Points: Question Given health and environmental concerns, is there a gadolinium-free imaging protocol to preoperatively evaluate gliomas comparable to the gadolinium-enhanced standard practice? Findings The proposed gadolinium-free diagnosis prediction decision tree for adult-type diffuse gliomas performed well, and gadolinium-enhanced MRI demonstrated only limited improvement in diagnostic accuracy. Clinical relevance Even inexperienced raters effectively classified adult-type diffuse gliomas using the gadolinium-free diagnosis prediction decision tree, which, until further validation, can be used alongside gadolinium-enhanced images to respect standard practice, despite this study showing that gadolinium-enhanced images hardly improved diagnostic accuracy.
AB - Objectives: To develop a gadolinium-free MRI-based diagnosis prediction decision tree (DPDT) for adult-type diffuse gliomas and to assess the added value of gadolinium-based contrast agent (GBCA) enhanced images. Materials and methods: This study included preoperative grade 2–4 adult-type diffuse gliomas (World Health Organization 2021) scanned between 2010 and 2021. The DPDT, incorporating eleven GBCA-free MRI features, was developed using 18% of the dataset based on consensus readings. Diagnosis predictions involved grade (grade 2 vs. grade 3/4) and molecular status (isocitrate dehydrogenase (IDH) and 1p/19q). GBCA-free diagnosis was predicted using DPDT, while GBCA-enhanced diagnosis included post-contrast images. The accuracy of these predictions was assessed by three raters with varying experience levels in neuroradiology using the test dataset. Agreement analyses were applied to evaluate the prediction performance/reproducibility. Results: The test dataset included 303 patients (age (SD): 56.7 (14.2) years, female/male: 114/189, low-grade/high-grade: 54/249, IDH-mutant/wildtype: 82/221, 1p/19q-codeleted/intact: 34/269). Per-rater GBCA-free predictions achieved ≥ 0.85 (95%-CI: 0.80–0.88) accuracy for grade and ≥ 0.75 (95%-CI: 0.70–0.80) for molecular status, while GBCA-enhanced predictions reached ≥ 0.87 (95%-CI: 0.82–0.90) and ≥ 0.77 (95%–CI: 0.71–0.81), respectively. No accuracy difference was observed between GBCA-free and GBCA-enhanced predictions. Group inter-rater agreement was moderate for GBCA-free (0.56 (95%-CI: 0.46–0.66)) and substantial for GBCA-enhanced grade prediction (0.68 (95%-CI: 0.58–0.78), p = 0.008), while substantial for both GBCA-free (0.75 (95%-CI: 0.69–0.80) and GBCA-enhanced (0.77 (95%-CI: 0.71–0.82), p = 0.51) molecular status predictions. Conclusion: The proposed GBCA-free diagnosis prediction decision tree performed well, with GBCA-enhanced images adding little to the preoperative diagnostic accuracy of adult-type diffuse gliomas. Key Points: Question Given health and environmental concerns, is there a gadolinium-free imaging protocol to preoperatively evaluate gliomas comparable to the gadolinium-enhanced standard practice? Findings The proposed gadolinium-free diagnosis prediction decision tree for adult-type diffuse gliomas performed well, and gadolinium-enhanced MRI demonstrated only limited improvement in diagnostic accuracy. Clinical relevance Even inexperienced raters effectively classified adult-type diffuse gliomas using the gadolinium-free diagnosis prediction decision tree, which, until further validation, can be used alongside gadolinium-enhanced images to respect standard practice, despite this study showing that gadolinium-enhanced images hardly improved diagnostic accuracy.
KW - Brain neoplasms
KW - Gadolinium
KW - Glioma
KW - Isocitrate dehydrogenase
KW - Magnetic resonance imaging
KW - Glioma/diagnostic imaging
KW - Reproducibility of Results
KW - Brain Neoplasms/diagnostic imaging
KW - Humans
KW - Middle Aged
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Contrast Media
KW - Neoplasm Grading
KW - Adult
KW - Female
KW - Aged
KW - Decision Trees
UR - https://www.scopus.com/pages/publications/85206991573
UR - https://www.mendeley.com/catalogue/81eb5467-e13a-3c72-a0e0-19060d7590ea/
U2 - 10.1007/s00330-024-11140-5
DO - 10.1007/s00330-024-11140-5
M3 - Article
C2 - 39425768
AN - SCOPUS:85206991573
SN - 0938-7994
VL - 35
SP - 1242
EP - 1254
JO - European Radiology
JF - European Radiology
IS - 3
M1 - 3
ER -